Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPERIOR: Ticagrelor Regimens vs Clopidogrel in CAD
NCT03381742Phase 3Completed
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ticagrelor in coronary artery disease (CAD) (4 arms), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoints: ADP-induced Inhibition of Platelet Aggregation at 5 days and Number of Participants With Bleeding (Major or Minor Bleeding) at 5 days. Started Dec 2017; status: completed.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03381742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381742.